Protopic

Country: Evrópusambandið

Tungumál: enska

Heimild: EMA (European Medicines Agency)

Kauptu það núna

Vara einkenni Vara einkenni (SPC)
13-02-2024
Opinber matsskýrsla Opinber matsskýrsla (PAR)
16-08-2011

Virkt innihaldsefni:

tacrolimus

Fáanlegur frá:

LEO Pharma A/S

ATC númer:

D11AH01

INN (Alþjóðlegt nafn):

tacrolimus

Meðferðarhópur:

Other dermatological preparations

Lækningarsvæði:

Dermatitis, Atopic

Ábendingar:

Flare treatmentAdults and adolescents (16 years of age and above)Treatment of moderate to severe atopic dermatitis in adults who are not adequately responsive to or are intolerant of conventional therapies such as topical corticosteroids.Children (two years of age and above)Treatment of moderate to severe atopic dermatitis in children (two years of age and above) who failed to respond adequately to conventional therapies such as topical corticosteroids.Maintenance treatmentMaintenance treatment of moderate to severe atopic dermatitis for the prevention of flares and the prolongation of flare-free intervals in patients experiencing a high frequency of disease exacerbations (i.e. occurring four or more times per year) who have had an initial response to a maximum of six weeks treatment of twice daily tacrolimus ointment (lesions cleared, almost cleared or mildly affected).

Vörulýsing:

Revision: 26

Leyfisstaða:

Authorised

Leyfisdagur:

2002-02-27

Upplýsingar fylgiseðill

                                39
B. PACKAGE LEAFLET
40
PACKAGE LEAFLET: INFORMATION FOR THE USER
PROTOPIC 0.03% OINTMENT
tacrolimus monohydrate
READ ALL OF THIS LEAFLET CAREFULLY BEFORE YOU START USING THIS
MEDICINE BECAUSE IT CONTAINS
IMPORTANT INFORMATION FOR YOU.
-
Keep this leaflet. You may need to read it again.
-
If you have any further questions, ask your doctor or pharmacist.
-
This medicine has been prescribed for you only. Do not pass it on to
others. It may harm them,
even if their signs of illness are the same as yours.
-
If you get any side effects, talk to your doctor or pharmacist. This
includes any possible side
effects not listed in this leaflet. See section 4.
WHAT IS IN THIS LEAFLET
1.
What Protopic is and what it is used for
2.
What you need to know before you use Protopic
3.
How to use Protopic
4.
Possible side effects
5.
How to store Protopic
6.
Contents of the pack and other information
1.
WHAT PROTOPIC IS AND WHAT IT IS USED FOR
The active substance of Protopic, tacrolimus monohydrate, is an
immunomodulating agent.
Protopic 0.03% ointment is used to treat moderate to severe atopic
dermatitis (eczema) in adults who
are not adequately responsive to or are intolerant of conventional
therapies such as topical
corticosteroids and in children (2 years of age and older) who failed
to respond adequately to
conventional therapies such as topical corticosteroids.
Once moderate to severe atopic dermatitis is cleared or almost cleared
after up to 6 weeks treatment of
a flare, and if you are experiencing frequent flares (i.e. 4 or more
per year), it may be possible to
prevent flares coming back or prolong the time you are free from
flares by using Protopic 0.03%
ointment twice weekly.
In atopic dermatitis, an over-reaction of the skin’s immune system
causes skin inflammation
(itchiness, redness, dryness). Protopic alters the abnormal immune
response and relieves the skin
inflammation and the itch.
2.
WHAT YOU NEED TO KNOW BEFORE YOU USE PROTOPIC
DO NOT USE PROTOPIC
•
If you are allergic to tacrolimus or any of the other ingredi
                                
                                Lestu allt skjalið
                                
                            

Vara einkenni

                                1
ANNEX I
SUMMARY OF PRODUCT CHARACTERISTICS
2
1.
NAME OF THE MEDICINAL PRODUCT
Protopic 0.03% ointment
2.
QUALITATIVE AND QUANTITATIVE COMPOSITION
1 g of Protopic 0.03% ointment contains 0.3 mg of tacrolimus as
tacrolimus monohydrate (0.03%).
Excipient with known effect
Butylhydroxytoluene (E321) 15 micrograms/g ointment.
For the full list of excipients, see section 6.1.
3.
PHARMACEUTICAL FORM
Ointment
A white to slightly yellowish ointment.
_ _
4.
CLINICAL PARTICULARS
4.1
THERAPEUTIC INDICATIONS
Protopic 0.03% ointment is indicated in adults, adolescents and
children from the age of 2 years.
Flare treatment
_Adults and adolescents (16 years of age and above)_
Treatment of moderate to severe atopic dermatitis in adults who are
not adequately responsive to or
are intolerant of conventional therapies such as topical
corticosteroids.
_Children (2 years of age and above) _
Treatment of moderate to severe atopic dermatitis in children who
failed to respond adequately to
conventional therapies such as topical corticosteroids.
Maintenance treatment
Treatment of moderate to severe atopic dermatitis for the prevention
of flares and the prolongation of
flare-free intervals in patients experiencing a high frequency of
disease exacerbations (i.e. occurring 4
or more times per year) who have had an initial response to a maximum
of 6 weeks treatment of twice
daily tacrolimus ointment (lesions cleared, almost cleared or mildly
affected).
4.2
POSOLOGY AND METHOD OF ADMINISTRATION
Protopic treatment should be initiated by physicians with experience
in the diagnosis and treatment of
atopic dermatitis.
Protopic is available in two strengths, Protopic 0.03% and Protopic
0.1% ointment.
Posology
Flare treatment
Protopic can be used for short-term and intermittent long-term
treatment. Treatment should not be
continuous on a long-term basis.
Protopic treatment should begin at the first appearance of signs and
symptoms. Each affected region of
the skin should be treated with Protopic until lesions are cleared,
almost cleared or mildly a
                                
                                Lestu allt skjalið
                                
                            

Skjöl á öðrum tungumálum

Upplýsingar fylgiseðill Upplýsingar fylgiseðill búlgarska 13-02-2024
Vara einkenni Vara einkenni búlgarska 13-02-2024
Opinber matsskýrsla Opinber matsskýrsla búlgarska 16-08-2011
Upplýsingar fylgiseðill Upplýsingar fylgiseðill spænska 13-02-2024
Vara einkenni Vara einkenni spænska 13-02-2024
Opinber matsskýrsla Opinber matsskýrsla spænska 16-08-2011
Upplýsingar fylgiseðill Upplýsingar fylgiseðill tékkneska 13-02-2024
Vara einkenni Vara einkenni tékkneska 13-02-2024
Opinber matsskýrsla Opinber matsskýrsla tékkneska 16-08-2011
Upplýsingar fylgiseðill Upplýsingar fylgiseðill danska 13-02-2024
Vara einkenni Vara einkenni danska 13-02-2024
Opinber matsskýrsla Opinber matsskýrsla danska 16-08-2011
Upplýsingar fylgiseðill Upplýsingar fylgiseðill þýska 13-02-2024
Vara einkenni Vara einkenni þýska 13-02-2024
Opinber matsskýrsla Opinber matsskýrsla þýska 16-08-2011
Upplýsingar fylgiseðill Upplýsingar fylgiseðill eistneska 13-02-2024
Vara einkenni Vara einkenni eistneska 13-02-2024
Opinber matsskýrsla Opinber matsskýrsla eistneska 16-08-2011
Upplýsingar fylgiseðill Upplýsingar fylgiseðill gríska 13-02-2024
Vara einkenni Vara einkenni gríska 13-02-2024
Opinber matsskýrsla Opinber matsskýrsla gríska 16-08-2011
Upplýsingar fylgiseðill Upplýsingar fylgiseðill franska 13-02-2024
Vara einkenni Vara einkenni franska 13-02-2024
Opinber matsskýrsla Opinber matsskýrsla franska 16-08-2011
Upplýsingar fylgiseðill Upplýsingar fylgiseðill ítalska 13-02-2024
Vara einkenni Vara einkenni ítalska 13-02-2024
Opinber matsskýrsla Opinber matsskýrsla ítalska 16-08-2011
Upplýsingar fylgiseðill Upplýsingar fylgiseðill lettneska 13-02-2024
Vara einkenni Vara einkenni lettneska 13-02-2024
Opinber matsskýrsla Opinber matsskýrsla lettneska 16-08-2011
Upplýsingar fylgiseðill Upplýsingar fylgiseðill litháíska 13-02-2024
Vara einkenni Vara einkenni litháíska 13-02-2024
Opinber matsskýrsla Opinber matsskýrsla litháíska 16-08-2011
Upplýsingar fylgiseðill Upplýsingar fylgiseðill ungverska 13-02-2024
Vara einkenni Vara einkenni ungverska 13-02-2024
Opinber matsskýrsla Opinber matsskýrsla ungverska 16-08-2011
Upplýsingar fylgiseðill Upplýsingar fylgiseðill maltneska 13-02-2024
Vara einkenni Vara einkenni maltneska 13-02-2024
Opinber matsskýrsla Opinber matsskýrsla maltneska 16-08-2011
Upplýsingar fylgiseðill Upplýsingar fylgiseðill hollenska 13-02-2024
Vara einkenni Vara einkenni hollenska 13-02-2024
Opinber matsskýrsla Opinber matsskýrsla hollenska 16-08-2011
Upplýsingar fylgiseðill Upplýsingar fylgiseðill pólska 13-02-2024
Vara einkenni Vara einkenni pólska 13-02-2024
Opinber matsskýrsla Opinber matsskýrsla pólska 16-08-2011
Upplýsingar fylgiseðill Upplýsingar fylgiseðill portúgalska 13-02-2024
Vara einkenni Vara einkenni portúgalska 13-02-2024
Opinber matsskýrsla Opinber matsskýrsla portúgalska 16-08-2011
Upplýsingar fylgiseðill Upplýsingar fylgiseðill rúmenska 13-02-2024
Vara einkenni Vara einkenni rúmenska 13-02-2024
Opinber matsskýrsla Opinber matsskýrsla rúmenska 16-08-2011
Upplýsingar fylgiseðill Upplýsingar fylgiseðill slóvakíska 13-02-2024
Vara einkenni Vara einkenni slóvakíska 13-02-2024
Opinber matsskýrsla Opinber matsskýrsla slóvakíska 16-08-2011
Upplýsingar fylgiseðill Upplýsingar fylgiseðill slóvenska 13-02-2024
Vara einkenni Vara einkenni slóvenska 13-02-2024
Opinber matsskýrsla Opinber matsskýrsla slóvenska 16-08-2011
Upplýsingar fylgiseðill Upplýsingar fylgiseðill finnska 13-02-2024
Vara einkenni Vara einkenni finnska 13-02-2024
Opinber matsskýrsla Opinber matsskýrsla finnska 16-08-2011
Upplýsingar fylgiseðill Upplýsingar fylgiseðill sænska 13-02-2024
Vara einkenni Vara einkenni sænska 13-02-2024
Opinber matsskýrsla Opinber matsskýrsla sænska 16-08-2011
Upplýsingar fylgiseðill Upplýsingar fylgiseðill norska 13-02-2024
Vara einkenni Vara einkenni norska 13-02-2024
Upplýsingar fylgiseðill Upplýsingar fylgiseðill íslenska 13-02-2024
Vara einkenni Vara einkenni íslenska 13-02-2024
Upplýsingar fylgiseðill Upplýsingar fylgiseðill króatíska 13-02-2024
Vara einkenni Vara einkenni króatíska 13-02-2024

Leitaðu viðvaranir sem tengjast þessari vöru

Skoða skjalasögu